Zacks Investment Research on MSN

Pfizer stock slides despite Q4 earnings beat and new obesity drug data

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks Consensus Estimate of 57 cents per share. Earnings rose 5% year over year.
Nasdaq

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer slips as analysts react to underwhelming outlook, obesity drug data

Pfizer (PFE) stock drops as analysts weigh in on mid-stage trial data for the company's obesity drug and its Q4 2025 earnings. Read more here.
PharmExec

ACIP Member Claims FDA Commissioner is Halting Decision to Remove Covid Vaccines from the Market: Report

According to public statements and social media posts from X, ACIP vice chair Robert Malone (a public ally of HHS secretary Robert F. Kennedy Jr.) publicly accused FDA Commissioner Marty Makary of ...